Pharmaceutical companies Boehringer ingelheim and Ablynx today jointly announced a major global strategic alliance aimed at developing a range of Nanobody® therapeutics.
Shares are sold by shares were held by CapMan Buyout X Fund A and CapMan Buyout X Fund B
Advent made a takeover offer of 165 pence per share in cash, which represents a 34% premium in July
Business strategy platform will expand its product and triple its team size
This is the fund's sixth realisation, following the sale of Vet Partners and Compass Community